Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Advancing stem cell-derived photoreceptor replacement therapy
Author Affiliations & Notes
  • Rachael A. Pearson
    King's College London, London, ENGLAND, United Kingdom
  • Footnotes
    Commercial Relationships   Rachael Pearson None
  • Footnotes
    Support  Medical Research Council UK (MR/V038559/1; MR/T002735/1); Fight for Sight (5139/5140); Moorfields Eye Charity (R190036A)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 10. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rachael A. Pearson; Advancing stem cell-derived photoreceptor replacement therapy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):10.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Effective treatment for reversing sight-loss caused by photoreceptor degeneration remains a major goal for current research. Here, I will discuss recent progress in the development of stem cell-derived photoreceptor replacement therapy, with a particular emphasis on cell suspension-based approaches and the treatment of advanced retinal disease. We have previously reported the restoration of retinal and visual function following the transplantation of human stem cell-derived cone photoreceptors, and are now examining the potential breadth of application, together with some of the challenges and promising prospects for re-establishing functional synaptic connectivity and donor cell polarisation in the aged and advanced disease environment.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×